retatrutide phase 2 trial obesity nejm 2023 triple agonist First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, GLP-1 & Glucagon hormone receptor drug leads to nearly 29% weight loss in first pivotal test! Eli Lilly announced positive topline results from the Retatrutide Phase 3: 28.7% Weight

Postmarketing reports of tirzepatide and selective GLP-1RAs suggest an increased risk of retained gastric content at the time of endoscopic procedures and rarer reports of periprocedural aspiration in patients who receive GLP-1RAs [16]

We aimed to gain new insights into metabolic abnormalities and shared characteristics between non-rejection and rejection conditions in kidney transplantation by analyzing single-cell metabolic gene expression profiles

Lacey Muinos Tester Persson C et al

Read the full Niacin + Acenocoumarol interaction Epimedium Whole Herb ExtractAnticoagulant/antiplatelet Drugs Moderate Interaction Summary Theoretically, horny goat weed might increase the risk of bleeding